<p>There are 175 fully characterized patient cases with relapsed precursor B-cell ALL (all tumor/normal pairs, 85 with relapse sample as well) that will make up Phase II of the TARGET  ALL dataset, each with gene expression, tumor and paired normal copy number analyses, and comprehensive next-generation sequencing to include whole</p>

TARGET: Acute Lymphoblastic Leukemia (ALL) Expansion Phase 2

Precursor Cell Lymphoblastic Leukemia-Lymphoma study with RNA-Seq, WGS + 2 more data on CRDC (1,199 participants)